Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €49.99 EUR
Change Today -3.30 / -6.19%
Volume 100.0
8AK On Other Exchanges
As of 2:11 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (8AK) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - €67.90
52 Week Low
10/13/14 - €30.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALKERMES PLC (8AK)

alkermes plc (8AK) Related Businessweek News

View More BusinessWeek News

alkermes plc (8AK) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.

1,300 Employees
Last Reported Date: 02/24/15
Founded in 1987

alkermes plc (8AK) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $854.7K
Total Annual Compensation: $630.6K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $468.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $468.1K
Chief Compliance Officer, Chief Legal Officer...
Total Annual Compensation: $459.4K
Compensation as of Fiscal Year 2014.

alkermes plc (8AK) Key Developments

Alkermes plc - Special Call

To discuss U.S. Food and Drug Administration (FDA) approval of ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia

FDA Approves Alkermes plc's ARISTADA™ for Treatment of Schizophrenia

Alkermes plc announced that the U.S. Food and Drug Administration has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch ARISTADA immediately. ARISTADA’s features, including a range of dose strengths and dosing interval options, are designed to address the individual needs of patients and challenges in the treatment of schizophrenia. As a long-acting injectable medicine, ARISTADA provides patients, clinicians and families the certainty that patients receive medication for this serious brain disorder. Long-acting injectable antipsychotics provide patients with blood concentrations of active drug that remain within a therapeutic range for an extended period of time1 and help healthcare providers to track patient adherence.

Alkermes plc Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 11:10 AM

Alkermes plc Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-17-2015 11:10 AM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €49.99 EUR -3.30

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.156.40 CHF +1.10
Depomed Inc $18.35 USD -1.56
Emergent BioSolutions Inc $28.34 USD -0.74
Impax Laboratories Inc $37.81 USD -0.78
Jazz Pharmaceuticals PLC $130.53 USD -2.27
View Industry Companies

Industry Analysis


Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.9x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at